Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
📍 How it ended
Argenx discontinued a Vyvgart study in Sjögren's disease after a futility flag was raised, causing shares to tumble. The company's stock price plunged following the surprise failure of the late-stage study. Meanwhile, Argenx was digesting a phase 2 win for a $2.2B celiac disease drug and preparing for a pivotal run.
Epilogue added 26d ago, after coverage quieted.
Coverage (7)
-
-
-
-
-
-
-
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run Fierce Biotech · 29d ago broke it first
Where it stands
- Velocity & Diffusion: Coverage escalated across 7 distinct news outlets with 7 published articles, achieving a live velocity of 5.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run" developed substantial multi-source reporting across the Business sector, tracked across 6 distinct newsrooms by Newsylist.
Key reporting was led by WSJ, Investor's Business Daily, Reuters and Yahoo Finance. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 28d ago.
Answered
What drove coverage for Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run?
Coverage spiked when 6 independent newsrooms published 6 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.